Belluscura Regulatory News (BELL)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company")

Launch of Next Generation X-PLOR Portable Oxygen Concentrator

The latest product in the ground-breaking X-PLOR range will be the first portable concentrator with a mobile app that will connect with phones, tablets, pulse oximeters and wearables

LONDON, U.K. AND PLANO, TX, U.S. (27 June 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces the launch of its Bluetooth® enabled, next generation X-PLOR® portable oxygen concentrator (previously described as the X-PLOR CX).

The next generation X-PLOR provides more oxygen by weight than any portable oxygen concentrator in its class and with its new Nomad Health™ App, patients can connect other Bluetooth® devices such as their iPhone® or Android phone, Nonin® or Masimo® pulse oximeters, and Fitbit® wearables. Patients will be able to track their oxygen usage, breathing rates, blood oxygen saturation levels, heart rate, sleep and other important biometric and environmental data. The patient can then share this important healthcare data with their provider.

With the launch of the next generation X-PLOR, Belluscura continues to add more sizable distributors and durable medical equipment providers to its distribution network.

Robert Rauker, CEO of Belluscura plc, said: "I am very excited about the launch of the next generation X-PLOR with the Nomad Health App. Our goal is to not only provide cutting edge medical devices, but to also improve patient outcomes with every new product we launch. We believe putting more health and environmental information in the hands of our patients will result in greatly improved long-term patient outcomes."

Patrick J Strollo, Jr, MD Pulmonologist and Non-executive Director of Belluscura, said: ""Telemonitoring of home oxygen therapy is the present not the future. The ability to connect to wearable biometric devices will help improve patient care."

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.